Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 57.82% is 28% above its 5-year average of 45.21%, near the high end of its 5-year range (31.21%–59.62%).
3.03% above its 12-month average of 56.12%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 59.62%.
GROSS MARGIN
57.82%
GROSS MARGIN AVG TTM
56.12%
GROSS MARGIN AVG 3Y
47.88%
GROSS MARGIN AVG 5Y
45.21%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+3.03%
CURRENT VS 3Y AVG
+20.77%
CURRENT VS 5Y AVG
+27.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+39.73%
vs the sector median at left
Market Cap
$34.97M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$33.63M
Gross Margin
49.68%
TTM Avg
60.09%
3Y Avg
64.56%
5Y Avg
72.92%
Market Cap
$33.61M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
10.20%
Market Cap
$33.29M
Gross Margin
57.46%
TTM Avg
78.73%
3Y Avg
89.36%
5Y Avg
76.24%
Market Cap
$35.52M
Gross Margin
39.56%
TTM Avg
49.73%
3Y Avg
-33.76%
5Y Avg
-21.28%
Market Cap
$32.93M
Gross Margin
83.79%
TTM Avg
85.97%
3Y Avg
84.60%
5Y Avg
84.69%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $34.35M | 57.82% | 56.12% | 47.88% | 45.21% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | 0.00% | 0.00% | 0.00% | 0.00% |
| Scilex Holding Company (SCLX)vs › | $33.63M | 49.68% | 60.09% | 64.56% | 72.92% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | 0.00% | 0.00% | 0.00% | 10.20% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | 57.46% | 78.73% | 89.36% | 76.24% |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | 39.56% | 49.73% | -33.76% | -21.28% |
| DocGo Inc. (DCGO)vs › | $35.76M | 30.12% | 32.64% | 32.93% | 33.24% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $32.93M | 83.79% | 85.97% | 84.60% | 84.69% |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | 0.00% | 0.00% | 0.00% | 15.78% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | 0.00% | 0.00% | 0.00% | 22.09% |
Gross Margin
57.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 59.62% |
| 2026-03-31 | 57.87% |
| 2025-12-31 | 58.51% |
| 2025-09-30 | 55.76% |
| 2025-06-30 | 48.83% |
| 2025-03-31 | 40.75% |
| 2024-12-31 | 42.50% |
| 2024-09-30 | 46.29% |
| 2024-06-30 | 44.49% |
| 2024-03-31 | 42.47% |
| 2023-12-31 | 36.19% |
| 2023-09-30 | 46.37% |
| 2023-06-30 | 42.73% |
| 2023-03-31 | 52.78% |
| 2022-12-31 | 39.43% |
| 2022-09-30 | 50.25% |
| 2022-06-30 | 38.76% |
| 2022-03-31 | 37.24% |
| 2021-12-31 | 31.21% |
| 2021-09-30 | 32.12% |
